Fig. 3From: Naringenin alters the pharmacokinetics of ranolazine in part through the inhibition of cytochrome P450 (3A4) and P-glycoproteinArea under the curve of ranolazine alone and when naringenin was present in SDS and MDS (n = 6). SDS, single-dose study; MDS, multi-dose studyBack to article page